Related Experiment Video
Updated: Apr 5, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Plasminogen Activator Inhibitor-1, Body Fat and Insulin Action in Aging Women
Abstract:
Plasminogen activator inhibitor-1 (PAI-1) over-expression is linked to obesity, insulin resistance, and age. We hypothesized that aerobically trained women athletes would have reduced PAI-1 regardless of age compared to sedentary controls and levels would be associated with hyperinsulinemia. Plasma PAI-1 was measured in women athletes who were young (YA, n=19, VO2max=53.7±1.1ml/kg/min) and older (OA, n=18, VO2max=46.6±1.5ml/kg/min) and compared to 19 sedentary controls (YC, n=6, VO2max=35.9±1.2ml/kg/min; OC, n=13, VO2max=22.1±1.7ml/kg/min). PAI-1 levels did not differ between YA and OA but was 23% higher in OC compared to OA (P<0.05). PAI-1 was inversely associated with VO2max, directly to %body fat, and subcutaneous abdominal fat, fasting leptin, insulin, and first-phase and second-phase insulin response during a hyperglycemic clamp. The current results suggest that older athletes have low PAI-1 levels possibly due to high levels of physical fitness, reduced body fat, and increased insulin action and may contribute to low atherothrombosis and improved cardiovascular health.
More Related Videos
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
10:37Author Spotlight: Decellularization-Based Quantification of Skeletal Muscle Fatty Infiltration
Published on: June 9, 2023
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...